Yerevan
Tbilisi
Moscow
Paris
Los Angeles
Beijing
English
Հայերեն Русский
Main Timeline Video Share
May the Holiday Warm Hearts: Idram and IDBank Support the Children of Heroes Beneficiaries of the "By Your Side" program at IDBank AraratBank Named Large CSR Company of the Year Idram Joins the Fight Against Food Insecurity Ucom’s Renovated Sales and Service Center in Yerevan Mall Reopens 1% idcoin instead of New Year’s suffering: practical tips Idram Junior Donated Books to Schools Big Christmas Market with Idram, IDBank and idplus Ucom Supports Wildlife Monitoring in Ararat Region IDBank, Idram, and idplus at the Big Christmas Market Converse Bank Deputy CEO and CFO, Grant Akopian, Elected to BACEE Board Ucom and SunChild NGO Install a Solar Plant in Alaverdi Kindergarten
Timeline
The Power of One Dram April Beneficiary: Davitbek Games NGOUcom and Impact Hub Yerevan Announce the Third Year of Green Innovation FellowshipUnibank Launches Referral Campaign “Invite Friends and Get Bonuses"Team Holding: The second phase of the placement of USD-denominated bonds has been completed. Underwriter - Freedom Broker Armenia. “A friend” needs money urgently. IDBank warns that trust can be exploited on social media.Denationalizing the ‘Map’ (Reflections on the ‘Real Armenia Ideology’)AraratBank at Leasing EXPO 2026: Special Leasing Offer for Energy-Efficient EquipmentUcom Offers Virtual Cloud Server (VPS) ServiceIDBank Participates in Regional Conference of the Union of Banks of Armenia, Presenting Innovative Tools for the SME SectorUp to 25% idcoin When Buying Airline Tickets with IDBank Premium CardsAcba bank and the U.S.-based Interactive Brokers have signed an agreementIDBank and Idram Alongside the “Matemik” NGOIDBank Participates in Regional Conference of the Union of Banks of ArmeniaConverse Bank Receives STP Excellence Award Once AgainUnibank to participate in Leasing Expo 2026 with a special offerAraratBank in Lori: Competitive Solutions for Business and Economic DevelopmentIDBank to Provide Scholarships Worth 35 Million Drams to 103 Artsakh Students at YSUUnibank joins the Partnership for Carbon Accounting Financials (PCAF)Safe environment – Equal opportunitiesAraratBank Receives STP Excellence Award from Commerzbank AG
All Timeline »
Life

Multiple sclerosis drug shows promising efficacy

The multiple sclerosis drug is showing promising efficacy in fighting relapses and reducing fatigue.

Back in March 2001, the US Food and Drug Administration approved a drug called ponosimod for use in adult patients with various types of multiple sclerosis. Only now there are research data that show that some drug reduces the number of relapses of the disease and can reduce fatigue - one of the characteristic symptoms of multiple sclerosis.

The respected scientific journal JAMA Neurology has found that ponesimod is more effective in fighting fatigue in multiple sclerosis than another commonly used drug called teriflunomide. It is superior to teriflunomide in reducing relapse rates and reducing the risk of new or existing lesions of myelin found on magnetic resonance imaging.

As reported by everydayhealth.com, ponesimod is used for various types of multiple sclerosis, including the most common relapsing remitting disease and active secondary progressive, which is the most severe. It is not accompanied by remissions and steadily leads to the disability of patients. It is people with this form of multiple sclerosis who show the appearance of new lesions of the myelin layer on MRI scans. Ponesimod must be taken once a day, treatment begins with a period of 14 days, then the doses are increased.